[e-farmacos] WHO Pharmaceuticals Newsletter No. 4, 2006

["Canas, Martin" <farmacol@femeba.org.ar>]

WHO Pharmaceuticals Newsletter No. 4, 2006

Estimadas y estimados,

Esta disponible el  WHO Pharmaceuticals Newsletter No. 4, 2006
con el siguiente indice:

Regulatory Matters

ADHD Drugs -- Labelling revised

 Cimicifuga racemosa (Black Cohosh) -- Concerns of liver injury 1

Fluoxetine -- Use extended to include paediatric patients  1

Natalizumab -- Reintroduced under Restricted Distribution/Risk Management Plan  2

SSRIs -- Challenges in pregnancy  2

SSRIs and SNRIs -- Combined use with anti-migraine medicines could be life-threatening 3

Telithromycin -- New safety information in label  3

Tipranavir -- Reports of intracranial haemorrhage 3

Triaminic Vapour Patch -- Risk of ingestion  4

Venlafaxine -- Information update to minimize overdose-side effects 4

Safety of Medicines

Angiotensin-converting enzyme (ACE) inhibitors -- Risk of birth defects  5

Chemotherapy/Immunosuppressive therapy -- Reactivation of hepatitis B virus infection  5

Colchicine -- Toxic in overdose: reminder  5

Colloids -- Safety considerations important in choosing resuscitation fluids  6

Dolasetron mesylate -- Contraindicated in patients below 18 years of age; not for use in post-operative nausea and vomiting  6

Gadodiamide -- Reports of nephrogenic systemic fibrosis  6

Nitrofurantoin -- Reports of interstitial lung disease 7

Proton pump inhibitors -- Update on reports of interstitial nephritis  7

Sibutramine -- ADR update from ADRAC  7

SSRIs and tricyclic antidepressants (TCAs) -- Potential for interaction  7

Feature

WHO Consultation on Global Monitoring of Adverse Events Following Immunization (AEFI) 

9-10 January 2006: A Report9

La direccion del ejemplar en la WHO-Ginebra:
http://www.who.int/medicines/publications/newsletter/pn2006_4.pdf 

Saludos,

Martin

Martin Canas
La Plata 
(Argentina)
macanas@netverk.com.ar